Satralizumab

Satralizumab is a humanized monoclonal antibody that is used for the treatment of neuromyelitis optica spectrum disorders (NMOSD). It is marketed under the brand name Enspryng and is developed by Roche.

Mechanism of Action

Satralizumab works by binding to the interleukin-6 (IL-6) receptor and inhibiting the signal transduction of IL-6, a cytokine that plays a key role in the inflammatory process in NMOSD.

Clinical Trials

In clinical trials, Satralizumab has shown to reduce the risk of NMOSD relapse. Side effects were similar to those seen in the general population, with the most common being nasopharyngitis and headache.

Approval

Satralizumab was approved for medical use in the United States in August 2020. In the European Union, it was granted a conditional marketing authorization in April 2021.

See Also

• Monoclonal antibodies
• Neuromyelitis optica
• Interleukin-6